^
High MHC-II signature
|
Bladder Cancer
|
High MHC-II signature
|
Bladder Cancer
|
sunitinib Sensitive: C3 – Early Trials
|
sunitinib Sensitive: C3 – Early Trials
|
High MHC-II signature
|
Bladder Cancer
|
High MHC-II signature
|
Bladder Cancer
|
NU7441 Sensitive: C3 – Early Trials
|
NU7441 Sensitive: C3 – Early Trials
|
High MHC-II signature
|
Bladder Cancer
|
High MHC-II signature
|
Bladder Cancer
|
docetaxel Sensitive: C3 – Early Trials
|
docetaxel Sensitive: C3 – Early Trials
|
High MHC-II signature
|
Bladder Cancer
|
High MHC-II signature
|
Bladder Cancer
|
cisplatin Sensitive: C3 – Early Trials
|
cisplatin Sensitive: C3 – Early Trials
|
